Q3 2017
Released Nov 8, 2017, before the open
10-Q filed Nov 8, 2017, 39 days after period end · 0001144204-17-057030
Q3 2017 · 10-Q
Revenue$0.00$0.00 no prior Q3 2016 on fileno prior Q2 2017 on file
Net Income-$4.70M-$4.70M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.22-$0.22 N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$4,766,059N/M
Operating Cash Flowderived-$4,565,753N/M
Free Cash Flowderived-$4,565,753N/M
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$4.70M | -$3.24M | -$6.37M | -$4.09M |
| EPS Diluted | -$0.22 | -$0.18 | -$0.35 | -$0.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR